Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,587,448 papers from all fields of science
Search
Sign In
Create Free Account
Recombinant EphB4-HSA Fusion Protein
Known as:
sEphB4-HSA
A recombinant fusion protein composed of the full-length extracellular domain (soluble) of human receptor tyrosine kinase ephrin type-B receptor 4…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).
Michael C Burns
,
V. Sagar
,
+6 authors
M. Hussain
2020
Corpus ID: 213626861
TPS274Background: The EphB4/EphrinB2 pathway is a promising therapeutic target for patients with mCRPC. EphB4 expression is…
Expand
2018
2018
A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA).
Jacob S. Thomas
,
H. Lenz
,
+11 authors
A. El-Khoueiry
2018
Corpus ID: 196491437
285Background: EphrinB4, a receptor kinase, is associated with stage and survival in epithelial cancers. sEphB4 is a fusion…
Expand
2016
2016
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas
Shilpa Bhatia
,
Kellen Hirsch
,
+10 authors
S. Karam
Scientific reports
2016
Corpus ID: 19026391
Members of the Eph family of receptor tyrosine kinases have been implicated in a wide array of human cancers. The EphB4 receptor…
Expand
2016
2016
A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D)
A. El-Khoueiry
,
B. Gitlitz
,
+15 authors
P. Gill
2016
Corpus ID: 78292136
2016
2016
Circulating tumor cell analysis in a first-in-human phase I study of sEphB4-HSA, an inhibitor of EphrinB2-EphB4 signaling
Cory M. Hugen
,
Gareth J Morrison
,
+11 authors
A. Goldkorn
2016
Corpus ID: 79370358
2014
2014
The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder
Xiuqing Li
,
W. W. Choi
,
+10 authors
Ren Liu
PloS one
2014
Corpus ID: 14755549
Effective treatment of transitional cell carcinoma (TCC) of the bladder requires early diagnosis. Identifying novel molecular…
Expand
2013
2013
EphB4 as a therapeutic target in mesothelioma
Ren Liu
,
B. Ferguson
,
+4 authors
V. Krasnoperov
BMC Cancer
2013
Corpus ID: 9433582
BackgroundMalignant pleural mesothelioma (MPM) often develops decades following exposure to asbestos. Current best therapy…
Expand
2012
2012
Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA.
Shuai Shi
,
Jing Liu
,
+4 authors
D. Volkin
Journal of pharmaceutical sciences
2012
Corpus ID: 2162608
The use of albumin fusion proteins as therapeutic drug candidates is an attractive approach to design novel biopharmaceuticals…
Expand
Highly Cited
2009
Highly Cited
2009
The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade.
J. Scehnet
,
E. Ley
,
+7 authors
P. Gill
Blood
2009
Corpus ID: 11536504
Kaposi sarcoma (KS) is associated with human herpesvirus (HHV)-8 and is dependent on the induction of vascular endothelial growth…
Expand
2009
2009
Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma.
R. C. Chan
,
B. Gutierrez
,
T. Ichim
,
F. Lin
Oncology reports
2009
Corpus ID: 17716867
Immunotherapy of cancer offers great promise, however translation into human studies has yielded relatively poor results to date…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE